help button home button Am J Pathol JNCI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by van der Pluijm, G.
Right arrow Articles by Löwik, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by van der Pluijm, G.
Right arrow Articles by Löwik, C.
(American Journal of Pathology. 2003;163:157-163.)
© 2003 American Society for Investigative Pathology

In Vitro and in Vivo Endochondral Bone Formation Models Allow Identification of Anti-Angiogenic Compounds

Gabri van der Pluijm*, Martine Deckers*, Bianca Sijmons*, Henny de Groot*, John Bird{dagger}, Ruth Wills{dagger}, Socrates Papapoulos*, Andy Baxter{dagger} and Clemens Löwik*

From the Department of Endocrinology,* Leiden University Medical Center, Leiden, the Netherlands and CellTech R&D Limited,{dagger} Cambridge, United Kingdom

A major obstacle in the study of angiogenesis and the testing of new agents with anti-angiogenic potential has been the lack of experimental models with predictive in vivo value. We describe here the combined use of in vitro and in vivo angiogenesis models that are based on endochondral bone development. This approach led to the identification of a new inhibitor of matrix metalloprotease (MMP) activity that inhibits neovascularization in vitro and in vivo while osteoclast invasion, which occurs simultaneously during bone development, remained unaffected. In contrast, the broad-spectrum MMP-inhibitor marimastat inhibited both in vitro angiogenesis and osteoclastogenesis dose-dependently but displayed severe toxic side effects in vivo. The combined use of these experimental models may, therefore, facilitate the discovery of mechanisms underlying angiogenesis and lead to identification of new pharmacological compounds with clinical efficacy and appropriate selectivity in the treatment of angiogenesis-dependent disorders like arthritis and cancer.




This article has been cited by other articles:


Home page
 J. Histochem. Cytochem.Home page
E. J. Kuiper, P. Roestenberg, C. Ehlken, V. Lambert, H. B. van Treslong-de Groot, K. M. Lyons, H.-J. T. Agostini, J.-M. Rakic, I. Klaassen, C. J.F. Van Noorden, et al.
Angiogenesis Is Not Impaired in Connective Tissue Growth Factor (CTGF) Knock-out Mice
J. Histochem. Cytochem., November 1, 2007; 55(11): 1139 - 1147.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by the American Society for Investigative Pathology.